Evidence map›Paper›PMID 25756239›Full record

ArticleThe American journal of gastroenterology2015

Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study.

Ivo Ditah, Badr Al Bawardy, Humberto C Gonzalez, Behnam Saberi, Callistus Ditah, Patrick S Kamath, Michael Charlton

Abstract read
PubMed Publisher
In one paragraph

Article in The American journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. [Study on the related factors of antiviral treatment in previously reported hepatitis C patients based on the Andersen model].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Hepatitis C Continuum of Care in a Treatment Center in Sub-Saharan Africa.Journal of clinical and experimental hepatology · 2018
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Observational
  15. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ivo DitahDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Badr Al BawardyDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Humberto C GonzalezDepartment of Transplant Surgery, Methodist University Hospital, University of Tennessee, Memphis, Tennessee, USA.
Behnam SaberiDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Callistus DitahUniversity of Michigan Medical School, Ann Arbor, Michigan, USA.
Patrick S KamathDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Michael CharltonHepatology and Liver Transplantation, Intermountain Medical Center, Salt Lake City, Utah, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIdentifying barriers to access to hepatitis C virus (HCV) treatment among screen detected subjects is critical for any public health strategy aimed at controlling HCV infection in the general population.

methodsData from the National Health and Nutrition Examination Survey HCV Follow-up study from 2001 to 2010 were used. Participants who tested positive for HCV were sent a letter informing them of their test results and advised to pursue further evaluation. Information on HCV transmission and its potential complications was also provided to all positive participants. These subjects were recontacted 6 months after notification to determine what action they had taken regarding the positive result.

resultsOf 38,025 participants, 502 tested positive for HCV infection, giving a prevalence of 1.3% (95% confidence interval (CI) 0.8%, 1.8%). A total of 205 subjects participated in the 6-month follow-up interview. Those who could not be reached were more likely to be less educated, injecting drugs, and not to have health insurance. Half (50.2%) of the positive individuals were not aware of their status before notification. A total of 166 (81%) had pursued further evaluation. Only 18 (26.9%) received therapy. The main reason for not receiving treatment was high cost (19.4%). In adjusted analysis, the only barrier to pursuing downstream HCV care was the lack of health insurance (2.76, 95% CI 1.54, 7.69; P=0.007).

conclusionsThis study suggests that the lack of health insurance may attenuate the theoretical benefits of a screening program that identifies asymptomatic HCV-infected individuals who are less likely to pursue downstream care.

Indexed as

AdultFemaleFollow-Up StudiesHealth Knowledge, Attitudes, PracticeHealth Services AccessibilityHepatitis CHumansInsurance CoverageInsurance, HealthInterviews as TopicMaleMass ScreeningMedically UninsuredMiddle AgedNutrition SurveysUnited States

Identifiers

PMID25756239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.